Mini Review
Cancer Gene Therapy (2009) 16, 807–809; doi:10.1038/cgt.2009.53; published online 28 August 2009
Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development
D D Rao1, N Senzer1,2, M A Cleary3 and J Nemunaitis1,2
- 1Gradalis Inc., Dallas, TX, USA
- 2Mary Crowley Cancer Research Centers, Dallas, TX, USA
- 3Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co. Inc., Seattle, WA, USA
Correspondence: Dr J Nemunaitis, Executive Medical Director, Mary Crowley Cancer Research Centers, 1700 Pacific Ave., Suite 1100, Dallas, TX 75201, USA. E-mail: jnemunaitis@marycrowley.org
Received 9 March 2009; Revised 27 June 2009; Accepted 8 July 2009; Published online 28 August 2009.
Abstract
This review considers comparisons of the off-target effects of siRNA to shRNA and their potential impact on the efficacy and toxicity of RNAi based therapeutics.
Keywords:
RNAi, siRNA, shRNA, miRNA, cancer therapy
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
Nature Biotechnology News and Views (01 Jul 2006)
Nature Methods News and Views (01 Sep 2007)
